Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors

23 February 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Optimization of binding affinities for ligands to their target protein is a primary objective in rational drug discovery. Herein we report on a collaborative study that evaluates various compounds designed to bind to the SET and MYND domain-containing protein 3 (SMYD3). SMYD3 is a histone methyltransferase and plays an important role in transcriptional regulation in cell proliferation, cell cycle and human carcinogenesis. Experimental measurements using the scintillation proximity assay show that the distributions of binding free energies from a large number of independent measurements exhibit non-normal properties. We use ESMACS (enhanced sampling of molecular dynamics with approximation of continuum solvent) and TIES (thermodynamic integration with enhanced sampling) protocols to rank the binding free energies and to provide detailed chemical insight into the nature of ligand−protein binding. Our results show that the 1-trajectory ESMACS protocol works well for the set of ligands studied here. Although one unexplained outlier exists, we obtain excellent statistical rankings across the set of compounds from the two protocols. ESMACS and TIES are again found to be powerful protocols for the accurate comparison of the binding free energies.

Keywords

ESMACS (enhanced sampling of molecular dynamics with approximation of continuum solvent)
TIES (thermodynamic integration with enhanced sampling)
Binding free energy
Non-normal distribution
Molecular dynamics simulation

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.